Properties (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
every 2 weeks
|
| gptkbp:approves |
gptkb:Canada
gptkb:European_Union gptkb:Japan gptkb:United_States gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:barrelLength |
high affinity for PD-1
|
| gptkbp:chemicalFormula |
C6420H9920N1716O1980S44
|
| gptkbp:clinicalTrials |
Phase 2
Phase 3 EMPOWER-CSCC-1 EMPOWER-Lung-1 KEYNOTE-689 |
| gptkbp:contraindication |
hepatitis
pneumonitis colitis endocrinopathies immune-mediated adverse reactions |
| gptkbp:developedBy |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:drugInterdiction |
linear pharmacokinetics
|
| gptkbp:endOfLife |
13 days
|
| gptkbp:firstAppearance |
2018-09-28
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cemiplimab
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:mandates |
advanced skin cancer
locally advanced skin cancer metastatic skin cancer unresectable skin cancer |
| gptkbp:marketedAs |
Regeneron_and_Sanofi
|
| gptkbp:patentStatus |
patented
|
| gptkbp:produces |
produced_in_Chinese_hamster_ovary_cells
|
| gptkbp:researchAreas |
oncology
cancer treatment biologics immunotherapy |
| gptkbp:route |
IV
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sells |
gptkb:Libtayo
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea rash pruritus |
| gptkbp:targets |
PD-1
|
| gptkbp:triggerType |
PD-1 inhibitor
|
| gptkbp:usedFor |
treatment of non-small cell lung cancer
treatment of cutaneous squamous cell carcinoma |
| gptkbp:weight |
146 kDa
|